| Source: |
| Type: |
| Adenosine triphosphate (ATP) is the source of energy for use and storage at the cellular level. Cellular ATP levels are critical for cell survival, and several reports have shown that reductions in cellular ATP levels can lead to apoptosis and other types of cell death in cancer cells, depending on the level of depletion. Adenosine triphosphate (ATP) is one of the main biochemical components of the tumor microenvironment (TME), where it can promote tumor progression or tumor suppression depending on its concentration and on the specific ecto-nucleotidases and receptors expressed by immune and cancer cells. Cancer cells, unlike normal cells, derive as much as 60% of their ATP from glycolysis via the “Warburg effect”, and the remaining 40% is derived from mitochondrial oxidative phosphorylation. |
| 1490- | RES, | Anticancer Potential of Resveratrol, β-Lapachone and Their Analogues |
| - | Review, | Var, | NA |
| 6420- | RES, | Resveratrol Regulates Mitochondrial Biogenesis and Fission/Fusion to Attenuate Rotenone-Induced Neurotoxicity |
| - | in-vivo, | Park, | NA |
| 6423- | RES, | Resveratrol Regulates Mitochondrial Biogenesis and Fission/Fusion to Attenuate Rotenone-Induced Neurotoxicity |
| - | vitro+vivo, | Park, | NA |
| 993- | RES, | Resveratrol reverses the Warburg effect by targeting the pyruvate dehydrogenase complex in colon cancer cells |
| - | in-vitro, | CRC, | Caco-2 | - | in-vivo, | Nor, | HCEC 1CT |
| 2566- | RES, | A comprehensive review on the neuroprotective potential of resveratrol in ischemic stroke |
| - | Review, | Stroke, | NA |
| 3092- | RES, | Resveratrol in breast cancer treatment: from cellular effects to molecular mechanisms of action |
| - | Review, | BC, | MDA-MB-231 | - | Review, | BC, | MCF7 |
| 3729- | RF, | Review of the Evidence that Transcranial Electromagnetic Treatment will be a Safe and Effective Therapeutic Against Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| - | in-vivo, | AD, | NA |
| 3026- | RosA, | Modulatory Effect of Rosmarinic Acid on H2O2-Induced Adaptive Glycolytic Response in Dermal Fibroblasts |
| - | in-vitro, | Nor, | NA |
| 3001- | RosA, | Therapeutic Potential of Rosmarinic Acid: A Comprehensive Review |
| - | Review, | Var, | NA |
| 3037- | RosA, | Unraveling rosmarinic acid anticancer mechanisms in oral cancer malignant transformation |
| - | in-vitro, | Oral, | SCC9 | - | in-vitro, | Oral, | HSC3 |
| 4898- | Sal, | Salinomycin as a potent anticancer stem cell agent: State of the art and future directions |
| - | Review, | Var, | NA |
| 4900- | Sal, | Anticancer Mechanisms of Salinomycin in Breast Cancer and Its Clinical Applications |
| - | Review, | BC, | NA |
| 4903- | Sal, | Salinomycin: A new paradigm in cancer therapy |
| - | Review, | Var, | NA |
| 4909- | Sal, | Salinomycin: Anti-tumor activity in a pre-clinical colorectal cancer model |
| - | vitro+vivo, | CRC, | NA |
| 5125- | Sal, | Salinomycin induced ROS results in abortive autophagy and leads to regulated necrosis in glioblastoma |
| - | in-vitro, | GBM, | NA |
| 1403- | SDT, | BBR, | From 2D to 3D In Vitro World: Sonodynamically-Induced Prooxidant Proapoptotic Effects of C60-Berberine Nanocomplex on Cancer Cells |
| - | in-vitro, | Cerv, | HeLa | - | in-vitro, | Lung, | LLC1 |
| 3195- | SFN, | AKT1/HK2 Axis-mediated Glucose Metabolism: A Novel Therapeutic Target of Sulforaphane in Bladder Cancer |
| - | in-vitro, | Bladder, | UMUC3 |
| 2445- | SFN, | Sulforaphane-Induced Cell Cycle Arrest and Senescence are accompanied by DNA Hypomethylation and Changes in microRNA Profile in Breast Cancer Cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 | - | in-vitro, | BC, | SkBr3 |
| 2448- | SFN, | Sulforaphane and bladder cancer: a potential novel antitumor compound |
| - | Review, | Bladder, | NA |
| 3298- | SIL, | Silibinin, a natural flavonoid, induces autophagy via ROS-dependent mitochondrial dysfunction and loss of ATP involving BNIP3 in human MCF7 breast cancer cells |
| - | in-vitro, | BC, | MCF7 |
| 3282- | SIL, | Role of Silymarin in Cancer Treatment: Facts, Hypotheses, and Questions |
| - | Review, | Var, | NA |
| 2410- | SIL, | Autophagy activated by silibinin contributes to glioma cell death via induction of oxidative stress-mediated BNIP3-dependent nuclear translocation of AIF |
| - | in-vitro, | GBM, | U87MG | - | in-vitro, | GBM, | U251 | - | in-vivo, | NA, | NA |
| 2415- | SK, | Shikonin induces programmed death of fibroblast synovial cells in rheumatoid arthritis by inhibiting energy pathways |
| - | in-vivo, | Arthritis, | NA |
| 2360- | SK, | Shikonin inhibits growth, invasion and glycolysis of nasopharyngeal carcinoma cells through inactivating the phosphatidylinositol 3 kinase/AKT signal pathway |
| - | in-vitro, | NPC, | HONE1 | - | in-vitro, | NPC, | SUNE-1 |
| 2359- | SK, | Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery |
| - | in-vivo, | Liver, | NA |
| 2190- | SK, | Shikonin exerts antitumor activity by causing mitochondrial dysfunction in hepatocellular carcinoma through PKM2-AMPK-PGC1α signaling pathway |
| - | in-vitro, | HCC, | HCCLM3 |
| 3045- | SK, | Cutting off the fuel supply to calcium pumps in pancreatic cancer cells: role of pyruvate kinase-M2 (PKM2) |
| - | in-vitro, | PC, | MIA PaCa-2 |
| 1284- | SK, | Shikonin induces ferroptosis in multiple myeloma via GOT1-mediated ferritinophagy |
| - | in-vitro, | Melanoma, | RPMI-8226 | - | in-vitro, | Melanoma, | U266 |
| 2125- | TQ, | Thymoquinone Selectively Kills Hypoxic Renal Cancer Cells by Suppressing HIF-1α-Mediated Glycolysis |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | RCC, | Caki-1 |
| 3431- | TQ, | PI3K-AKT Pathway Modulation by Thymoquinone Limits Tumor Growth and Glycolytic Metabolism in Colorectal Cancer |
| - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | SW48 |
| 2454- | Trip, | Natural product triptolide induces GSDME-mediated pyroptosis in head and neck cancer through suppressing mitochondrial hexokinase-ΙΙ |
| - | in-vitro, | HNSCC, | HaCaT | - | in-vivo, | NA, | NA |
| 2411- | UA, | Ursolic acid in health and disease |
| - | Review, | Var, | NA |
| 2350- | UA, | Ursolic acid-mediated changes in glycolytic pathway promote cytotoxic autophagy and apoptosis in phenotypically different breast cancer cells |
| - | in-vitro, | BC, | MCF7 | - | in-vitro, | BC, | MDA-MB-231 |
| 5021- | UA, | Anticancer effect of ursolic acid via mitochondria-dependent pathways |
| - | Review, | Var, | NA |
| 6412- | Uro, | EGCG, | A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer’s Disease |
| - | in-vivo, | AD, | NA |
| 4869- | Uro, | Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges |
| - | Review, | AD, | NA | - | Review, | Park, | NA | - | Review, | Stroke, | NA |
| 4871- | Uro, | DHA, | LT, | A Synergistic Combination of DHA, Luteolin, and Urolithin A Against Alzheimer’s Disease |
| - | in-vitro, | AD, | NA |
| 4874- | Uro, | EGCG, | A Combination Therapy of Urolithin A+EGCG Has Stronger Protective Effects than Single Drug Urolithin A in a Humanized Amyloid Beta Knockin Mice for Late-Onset Alzheimer's Disease |
| - | in-vivo, | AD, | NA |
| 4314- | VitB1/Thiamine, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4037- | VitB12, | FA, | Mechanistic Link between Vitamin B12 and Alzheimer’s Disease |
| - | Review, | AD, | NA |
| 4315- | VitB2, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4317- | VitB5, | Unraveling the molecular mechanisms of vitamin deficiency in Alzheimer's disease pathophysiology |
| - | Review, | AD, | NA |
| 4330- | VitB5, | Metabolic changes and inflammation in cultured astrocytes from the 5xFAD mouse model of Alzheimer’s disease: Alleviation by pantethine |
| - | in-vivo, | AD, | NA |
| 3143- | VitC, | ATO, | Vitamin C enhances the sensitivity of osteosarcoma to arsenic trioxide via inhibiting aerobic glycolysis |
| - | in-vitro, | OS, | NA |
| 3145- | VitC, | Vitamin C inhibits the growth of colorectal cancer cell HCT116 and reverses the glucose‐induced oncogenic effect by downregulating the Warburg effect |
| - | in-vitro, | CRC, | HCT116 |
| 3138- | VitC, | The Hypoxia-inducible Factor Renders Cancer Cells More Sensitive to Vitamin C-induced Toxicity |
| - | in-vitro, | RCC, | RCC4 | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | BC, | MDA-MB-435 | - | in-vitro, | Ovarian, | SKOV3 | - | in-vitro, | Colon, | SW48 | - | in-vitro, | GBM, | U251 |
| 1067- | VitC, | Vitamin C activates pyruvate dehydrogenase (PDH) targeting the mitochondrial tricarboxylic acid (TCA) cycle in hypoxic KRAS mutant colon cancer |
| - | in-vivo, | CRC, | NA |
| 627- | VitC, | High-Dose Vitamin C for Cancer Therapy |
| - | Review, | Var, | NA |
| 633- | VitC, | Diverse antitumor effects of ascorbic acid on cancer cells and the tumor microenvironment |
| - | Analysis, | Var, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:% Target#:21 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid